MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-10-2026
MediciNova Net Debt 2011-2026 | MNOV
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt MediciNova
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -30.6 M | -40 M | -50.4 M | -17.8 M | -70.6 M | -60 M | -63.8 M | -62.3 M | -28 M | -24.1 M | -22.1 M | -11.7 M | -6.7 M | -4.01 M | -15.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -4.01 M | -70.6 M | -33.8 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M |  Germany |
 |
Amgen
AMGN
|
41 B | $ 349.77 | 0.57 % | $ 188 B |  USA |
 |
Amphastar Pharmaceuticals
AMPH
|
457 M | $ 19.23 | -1.38 % | $ 899 M | USA |
 |
Altimmune
ALT
|
-9.22 M | $ 3.44 | 2.99 % | $ 303 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-187 M | $ 1.4 | 2.19 % | $ 357 M |  Britain |
 |
Aytu BioScience
AYTU
|
-19.9 M | $ 2.63 | 0.77 % | $ 16.5 M | USA |
 |
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
-195 M | $ 218.06 | -1.72 % | $ 5 B |  Danmark |
 |
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | USA |
 |
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | USA |
 |
Benitec Biopharma
BNTC
|
-1.92 M | $ 11.19 | 1.91 % | $ 461 M | USA |
 |
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-3.44 M | - | 10.36 % | $ 9.8 M | USA |
 |
Compugen Ltd.
CGEN
|
-5.05 M | $ 2.09 | - | $ 195 M |  Israel |
 |
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - |  Russia |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-5.64 M | $ 0.61 | -1.3 % | $ 6.99 M | Israel |
 |
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | USA |
 |
Cellectis S.A.
CLLS
|
-206 M | $ 3.42 | 2.4 % | $ 116 M | France |
 |
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | Israel |
 |
Cullinan Management
CGEM
|
-85.6 M | $ 12.84 | 0.78 % | $ 774 M | USA |
 |
Atreca
BCEL
|
33.1 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
-33.1 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-3.56 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
-56.5 M | - | -10.95 % | $ 876 K | USA |
 |
CorMedix
CRMD
|
-143 M | $ 6.42 | 2.72 % | $ 462 K | USA |
 |
Cara Therapeutics
CARA
|
-9.78 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-42.5 M | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
-23.8 M | - | -74.18 % | $ 955 K | USA |
 |
Checkpoint Therapeutics
CKPT
|
-40.8 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
293 M | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | Germany |
 |
Denali Therapeutics
DNLI
|
-158 M | $ 21.09 | 4.56 % | $ 3.47 B | USA |
 |
Dyadic International
DYAI
|
-6.38 M | $ 0.86 | -8.51 % | $ 24.8 M | USA |
 |
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-107 M | $ 4.42 | 4.25 % | $ 734 M | Canada |
 |
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | USA |
 |
AIkido Pharma
AIKI
|
-1.04 M | - | 1.93 % | $ 17.4 M | USA |